Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.69 |
| ▸ | CDC25B | P30305 | 1/20 | 0.69 |
| ▸ | CDC25C | P30307 | 1/20 | 0.69 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11213828 | 0.86 | SREBF2 (0.82) | SREBF2KDM4EKMT2AARGAA | |
| SCHEMBL11212983 | 0.86 | SREBF2 (0.82) | SREBF2KDM4EKMT2AARGAA | |
| SCHEMBL11215130 | 0.86 | SREBF2 (0.82) | SREBF2KDM4EKMT2AARGAA | |
| SCHEMBL23743150 | 0.86 | CDC25A (0.68) | CDC25ACDC25BCDC25CSREBF2KDM4E | |
| SCHEMBL11464717 | 0.84 | SREBF2 (0.79) | SREBF2KDM4EKMT2AARGAA | |
| SCHEMBL2781370 | 0.84 | KDM4E (0.85) | SREBF2KDM4EKMT2AARGAA | |
| SCHEMBL23743157 | 0.84 | RAB9A (0.71) | CDC25ACDC25BCDC25CKDM4EGAA | |
| SCHEMBL17336883 | 0.82 | EIF4E (0.56) | CDC25ACDC25BCDC25CSREBF2KDM4E | |
| SCHEMBL3600301 | 0.82 | CDC25A (0.56) | CDC25ACDC25BCDC25CKDM4EKMT2A | |
| SCHEMBL12871328 | 0.81 | EIF4E (0.60) | CDC25ACDC25BCDC25CKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117205-A1 | BICYCLIC PYRIDINE DERIVATIVE AND SALT THEREOF, AND HARMFUL ORGANISM CONTROL AGENT CHARACTERIZED BY CONTAINING SAID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | 北興化学工業株式会社 | 2024-06-06 | — | — | WO | disclosed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| CN-101663298-A | Thiazole derivatives as modulators of g protein-coupled receptors | IRM LLC | 2010-03-03 | — | — | CN | disclosed |
| US-20100022592-A1 | THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022592-A1 | THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| EP-2121675-A1 | THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2009-11-25 | — | — | EP | disclosed |
| US-20090042857-A1 | Novel Pharmaceutical | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1987827-A1 | NOVEL PHARMACEUTICAL | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008103500-A1 | THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2008-08-28 | — | — | WO | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | CDC25A 3883/4885CDC25B 3380/4885CDC25C 3692/4885 |
| US-20090042857-A1 | Novel Pharmaceutical | AR, NR5A1, NR5A2 | CDC25A 3991/4885CDC25B 3755/4885CDC25C 3997/4885 |
| US-20100022592-A1 | THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS | GPR119, GPR65, GPR180 | CDC25A 3955/4885CDC25B 3578/4885CDC25C 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.